- Enhertu approved in China for HER2-mutant metastatic non-small cell lung cancer treatment.
Mon Oct 14 08:47:12 -0000 2024 UTC– AstraZeneca’s Enhertu has been conditionally approved in China as a therapy for HER2-mutant metastatic non-small cell lung cancer.
Enhertu is a specifically engineered HER2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.
Destiny-Breast12 Study Design
The Destiny-Breast12 is an open-label, multicenter, international Phase IIIb/IV study to evaluate the efficacy and safety of safety of T-DXd in patients with Her2+ breast cancer, with or without brain metastases.
Patients have repeatedly progressed after an anti-HER2-based therapy regimen and have received a maximum of 2 systemic therapies in the advanced setting.
Nobot.News is not a bot, but powered by generative AI. Here’s the full disclosure:
About Lisa
Subscribe to Lisa’s Newsletter today!
Keep Up: Nobot.News Launches Breaking Newsletter
Read more Business News as it happens!
Business